Range of qualified clients: CDEC reviewed the uncertainty in the quantity of sufferers with moderately extreme to extreme hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific gurus consulted by CADTH indicated that some sufferers who're classified as having moderate or reasonable condition might have a severe bleeding phenotype, which https://andremstde.suomiblog.com/facts-about-hemgenix-revealed-51460004